ArcticZymes Technologies ASA (OSL:AZT) Margin of Safety % (DCF Dividends Based): N/A (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OSL:AZT ArcticZymes Technologies ASA OSL:AZT
78 GF Score
Price kr18.95
GF Value kr24.75
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is ArcticZymes Technologies ASA Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

ArcticZymes Technologies ASA's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

OSL:AZT vs VRTX, REGN, ALNY: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, ArcticZymes Technologies ASA's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ArcticZymes Technologies ASA Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArcticZymes Technologies ASA's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where ArcticZymes Technologies ASA's Margin of Safety % (DCF Dividends Based) falls into.


OSL:AZT
78GF Score
ArcticZymes Technologies ASA OSL:AZT
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is ArcticZymes Technologies ASA (OSL:AZT) Overvalued in 2026?

Based on GuruFocus' analysis, ArcticZymes Technologies ASA stock appears to be undervalued. The current stock price of kr18.95 is trading 23.4% below its estimated GF Value™ of kr24.75. GuruFocus considers ArcticZymes Technologies ASA to be Modestly Undervalued.

Key valuation signals for OSL:AZT:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: kr24.75 vs. price of kr18.95 (23.4% below fair value)
  • GF Score™: 78/100 with 1 warning sign

No single metric tells the full story. See the OSL:AZT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ArcticZymes Technologies ASA Business Description

Other Exchanges BIOTECO:Sweden0DRV:UK
Address Sykehusveien 23, Tromso, NOR, 9294
ArcticZymes Technologies ASA is a biotechnology company. The company is engaged in developing, producing, and marketing immune-modulating beta-glucans and novel recombinant enzymes for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing. The company's products include Woulgan wound gel, Feed Ingredient (M-Glucan), Nutraceuticals (M-Gard), Recombinant enzymes, and others. The company reports in two operating segments, Enzymes and Corporate. Geographically, it derives a majority of revenue from the USA followed by Lithuania, Norway, Germany, France, Italy, UK, Other countries in Europe, and Rest of world.
78GF Score

Get the complete analysis for OSL:AZT

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr18.95
Price
kr24.75
GF Value